Trial Profile
A Single Arm Phase II Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Roche
- 23 May 2013 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 04 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2010-019051-21).